Physician profile
Sharon Molinas
NPI 1063416659
$3,052.42
in general payments reported to CMS, 2019-2025
18 companies · $759 in 2025
The $759 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $49.66 · 2021: $128 · 2022: $622 · 2023: $515 · 2024: $670 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,874 · Education: $30.40 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.22 |
| Education | $30.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,079.31 | 2019-2025 | |
| Gilead Sciences, INC. | $847.48 | 2019-2025 | |
| Pfizer INC. | $220.73 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $173.16 | 2023-2025 | Rebyota |
| Qol Medical, LLC | $143.36 | 2019-2020 | |
| Janssen Biotech, INC. | $137.20 | 2020-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $75.82 | 2022-2024 | Gattex, Eohilia |
| Intercept Pharmaceuticals, INC. | $73.78 | 2024-2025 | |
| Celgene Corporation | $52.92 | 2021-2022 | |
| Ardelyx, INC. | $49.19 | 2022 | |
| Lilly USA, LLC | $42.34 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $32.15 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $27.83 | 2025 | Rezdiffra |
| Amgen INC. | $24.61 | 2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $23.25 | 2023 | Terlivaz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $19.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.28 | 2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Molinas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.